Home  »  Market Wire  »  PuriCore Successfully Completes Pre-IND Meeting With the FDA on PR022 for Atopic Dermatitis

PuriCore Successfully Completes Pre-IND Meeting With the FDA on PR022 for Atopic Dermatitis

MALVERN, PA–(Marketwired – Jun 9, 2016) –  PuriCore plc (AIM: PURI)

Source: http://www.marketwired.com/mw/release.do?id=2132788&sourceType=3

About the Author

has written 21643 stories on this site.

«
»
Copyright © 2010-2019 strategicbusinessnews.com